American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Thomson Scientific, 77 Hatton Garden, London, EC1N 8JS, UK. alexandra.kibble@thomson.com
Alexandra
A
Kibble
Jaya
J
Shumoogam
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use; D000077157:Sorafenib; D000077210:Sunitinib; D018581:Technology Transfer; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000068258:Bevacizumab; C401859:temsirolimus; D000077157:Sorafenib; D000077210:Sunitinib; D020123:Sirolimus